Skip to main content
Premium Trial:

Request an Annual Quote

Eisai to Use BioSeek's Drug Modeling Platform

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asterand subsidiary BioSeek will collaborate on multiple oncology and inflammation-focused projects with the Japanese pharmaceutical company Eisai, Asterand said today.

Under the two-year agreement, the BioMap platform, which includes cell-based models designed to replicate interactions that are found in pharmacology and toxicology, will be used in research projects in both the US and Japan.

The BioMap platform provides a database of reference profiles that can be compared to patterns and changes caused by drugs in order to provide insight into properties of compounds, such as their on-and off-target effects, dose responses, and discrimination of closely related compounds.

Specific financial terms of the agreement were not released, but they include license fees and milestone payments, said Asterand.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.